Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-22T07:31:32.589Z Has data issue: false hasContentIssue false

Maintenance Strategies in Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Extract

A key consideration in the discussion of maintenance treatment in schizophrenia is how to first help bring patients to the point where acute psychopathology is sufficiently controlled, so that we can focus on consolidating the gains achieved and prevent a recurrence of illness.

The different phases of treatment and response in schizophrenia include the acute phase, wherein we look for response and resolution; remission, where we control symptoms to levels of mild or less and work toward preventing relapse or any exacerbation of psychopathology; and recovery, meaning the ability to function in the community in the workplace, school, family roles, etc.

In preparing patients with schizophrenia for maintenance treatment, clinicians must ensure that they have done everything possible to alleviate the acute signs and symptoms of illness to the extent possible.

There are several questions to consider at this stage: How much improvement is enough? When do we change treatments, and why? What about adverse effects and the locus of care? In the context of this process of deciding how to bring about the best possible treatment response, we must consider that, if a patient is not responding, the diagnosis may need to be reevaluated. Adherence must be assessed and blood levels should be done (if feasible) to ensure that patients have an adequate amount of medication in their system. If blood levels are unavailable and adherence is an issue, the use of long-acting injectable medication should be considered. The clinician might decide to alterthe medication dose—to increase it, or perhaps decrease it if significant side effects are impeding therapeutic response. Adjunct medications or a switching strategy may be employed. Non-pharmacologic therapy, such as cognitive behavioral therapy, which can be effective at reducing symptoms of schizophrenia, should also be considered.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Malik, N, Kingdon, D, Pelton, J, Mehta, R, Turkington, D. Effectiveness of brief cognitive-behavioral therapy for schizophrenia delivered by mental health nurses: relapse and recovery at 24 months. J Clin Psychiatry. 2009;70(2):201207.CrossRefGoogle ScholarPubMed
2.Leucht, S, Kane, JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J Clin Psychiatry. 2006;67(11):18131814.CrossRefGoogle ScholarPubMed
3.Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006:31(10):23182325.CrossRefGoogle ScholarPubMed
4.Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799812.CrossRefGoogle Scholar
5.Agid, O, Kapur, S, Arenovich, T, Zipursky, RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Sen Psychiatry. 2003;60(12):12281235.CrossRefGoogle Scholar
6.Leucht, S, Busch, R, Hamann, J, Kissling, W, Kane, JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57(12):15431549.CrossRefGoogle Scholar
7.Kane, JM, Leucht, S, Carpenter, D, Docherty, JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64 (Suppl 12):519.Google ScholarPubMed
8.Kinon, BJ, Chen, L, Ascher-Svanum, H, Stauffer, VL, Kollack-Walker, S, Sniadecki, JL, et al.Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102(1–3):230240.CrossRefGoogle ScholarPubMed
9.Liu-Seifert, H, Adams, DH, Kinon, BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.CrossRefGoogle ScholarPubMed
10.Ascher-Svanum, H, Nyhuis, AW, Faries, DE, Kinon, BJ, Baker, RW, Shekhar, A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6):11631171.CrossRefGoogle ScholarPubMed
11.Andreasen, NC, Carpenter, WT Jr., Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441449.CrossRefGoogle ScholarPubMed
12.Leucht, S, Barnes, TR, Kissling, W, Engel, RR, Correll, C, Kane, JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized; controlled trials. Am J Psychiatry. 2003;160(7):12091222.CrossRefGoogle ScholarPubMed
13.Robinson, DG, Woerner, MG, Delman, HM, Kane, JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull. 2005;31(3):705722.CrossRefGoogle ScholarPubMed
14.Kane, JM. Schizophrenia. N Engl J Med. 1996;334(1):3441.CrossRefGoogle ScholarPubMed
15.Kane, JM, Rabiner, CJ. Studies of maintenance pharmacotherapy in schizophrenia: the Hillside Series. Psychiatr Hosp. 1982;13(2):4749.Google ScholarPubMed
16.Lieberman, JA, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):12091223.CrossRefGoogle ScholarPubMed
17.Blackwell, B. The drug defaulter. Clin Pharmacol Ther. 1972;13(6):841848.CrossRefGoogle ScholarPubMed
18.Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Senrv. 2004;55(8):886891.Google ScholarPubMed
19.Haynes, RB, Sackett, DL, Gibson, ES, et al.Improvement of medication compliance in uncontrolled hypertension. Lancet. 1976;1(7972): 12651268.CrossRefGoogle ScholarPubMed
20.Nose, M, Barbui, C, Tansella, M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. PsycholMed. 2003;33(7):11491160.Google ScholarPubMed
21.Hirsch, SR, Weinberger, DR. Schizophrenia. Oxford; Cambridge, Mass., USA: Blackwell Science; 1995.Google Scholar
22.Weiden, P, Rapkin, B, Zygmunt, A, Mott, T, Goldman, D, Frances, A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995;46(10):10491054.Google ScholarPubMed
23.Herings, RM, Erkens, JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423424.CrossRefGoogle ScholarPubMed
24.Dolder, CR, Lacro, JP, Dunn, LB, Jeste, DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159(1):103108.CrossRefGoogle Scholar
25.Spaniel, F, Vohlidka, P, Hrdlicka, J, et al.ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Bes. 2008;98(1–3):312317.CrossRefGoogle ScholarPubMed
26.Shea, SC. Improving Medication Adherence: How to Talk with Patients About Their Medications. Philadelphia, Pa.: Wolters Kluwer Health; 2006.Google Scholar